Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for pediatric STEC-HUS
ISRCTN89553116Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of eculizumab in hemolytic uremic syndrome (HUS) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Started Aug 2017; status: completed.
02
Drugs
eculizumab
03
Conditions
hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on ISRCTN89553116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89553116.